Cancer Stem Cell News Volume 5.43 | Nov 2 2016

TOP STORY

Single-Cell RNA-Seq Supports a Developmental Hierarchy in Human Oligodendroglioma

Investigators profiled 4,347 single cells from six IDH1 or IDH2 mutant human oligodendrogliomas by RNA sequencing (RNA-seq) and reconstructed their developmental programs from genome-wide expression signatures. The authors infer that most cancer cells are differentiated along two specialized glial programs, whereas a rare subpopulation of cells is undifferentiated and associated with a neural stem cell expression program. [Nature] Abstract | Press Release

(Ranked by impact factor of the journal)

Lgr6 Labels a Rare Population of Mammary Gland Progenitor Cells that Are Able to Originate Luminal Mammary Tumors

The identities of stem/progenitor cell populations, as well as tumor-initiating cells that give rise to breast cancer, are incompletely understood. The authors showed that Lgr6 marks rare populations of cells in both basal and luminal mammary gland compartments in mice. [Nat Cell Biol] Abstract

High-Throughput Screening in Niche-Based Assay Identifies Compounds to Target Preleukemic Stem Cells

Researchers designed a robust protocol for high-throughput screening of compounds that target primary preleukemic stem cells maintained in a niche-like environment, on stromal cells that were engineered for optimal NOTCH1 activation. [J Clin Invest] Full Article

Stromal PTEN Inhibits the Expansion of Mammary Epithelial Stem Cells through Jagged-1

While prior studies highlighted a tumor suppressive role for stromal phosphatase and tensin homolog (PTEN), how the adjacent normal epithelium transforms in response to PTEN loss was not previously addressed. To identify these early events, scientists evaluated both phenotypic and genetic changes within the pre-neoplastic mammary epithelium of mice with and without stromal PTEN expression. [Oncogene] Abstract

HULC Cooperates with MALAT1 to Aggravate Liver Cancer Stem Cells Growth through Telomere Repeat-Binding Factor 2

Scientists demonstrated HULC, MALAT1 and telomere repeat-binding factor 2 are highly expressed in human hepatocellular carcinoma tissues, and HULC plus MALAT1 overexpression drastically promotes the growth of liver cancer stem cells. [Sci Rep] Full Article

Infantile Hemangioma Originates From A Dysregulated But Not Fully Transformed Multipotent Stem Cell

To understand the process of hemangioma-genesis researchers characterized the progenitor hemangioma-derived stem cell and its lineage and non-lineage derivatives. [Sci Rep] Full Article

Upregulation of miR-99a is Associated with Poor Prognosis of Acute Myeloid Leukemia and Promotes Myeloid Leukemia Cell Expansion

To dissect the microRNA (miRNA) expression signature of relapse in acute myeloid leukemia (AML), scientists performed miRNA array analysis using enriched leukemia stem cells from paired bone marrow samples of an AML patient at different disease stages. [Oncotarget] Full Article

Dual Inhibition of PDK1 and Aurora Kinase A: An Effective Strategy to Induce Differentiation and Apoptosis of Human Glioblastoma Multiforme Stem Cells

Researchers explored the molecular mechanisms at the basis of a simultaneous phosphoinositide-dependent kinase-1 (PDK1)/aurora kinase A (AurA) inhibition in different glioblastoma multiforme (GBM) cell lines, as well as in a GBM-derived stem-like culture. [ACS Chem Neurosci] Abstract

miR-92a-3p Exerts Various Effects in Glioma and Glioma Stem-Like Cells Specifically Targeting CDH1/β-Catenin and Notch-1/Akt Signaling Pathways

Investigators applied methyl-thiazolyl-tetrazolium assay and transwell assay to measure the proliferation rate and metastatic potential of glioma cells. [Int J Mol Sci] Full Article

Allogeneic Stem Cell Transplantation: A Historical and Scientific Overview

The authors discuss the current science of hematopoietic stem cell transplant from a historical perspective, highlighting major discoveries. [Cancer Res] Abstract

Visit our reviews page to see a complete list of reviews in the cancer stem cell research field.

Pioneering Drug Discovery Company Bridge Medicines Launched to Advance Promising Early Technologies in Major Academic Institutions through Human Proof of Concept

Memorial Sloan Kettering Cancer Center, The Rockefeller University and Weill Cornell Medicine announced that they have established a new drug discovery company called Bridge Medicines. Launched in partnership with Takeda Pharmaceutical Company Ltd. and healthcare investment firms Bay City Capital and Deerfield Management, Bridge Medicines completes a path from concept to drug candidate to efficiently and rapidly develop innovative therapeutics for treating human diseases. [Memorial Sloan Kettering Cancer Center] Press Release

ARIAD Announces U.S. Food and Drug Administration Acceptance of NDA Filing for Brigatinib

ARIAD Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has accepted for review the New Drug Application (NDA) for ARIAD’s investigational oral anaplastic lymphoma kinase (ALK) inhibitor, brigatinib, in patients with metastatic ALK-positive (ALK+) non-small cell lung cancer who have progressed on crizotinib. [ARIAD Pharmaceuticals, Inc.] Press Release

Onxeo Announces Promising Results from Preclinical Study of Beleodaq^® Combination with Checkpoint Inhibitors

Onxeo S.A. announced promising results from preclinical studies evaluating the potential of its already peripheral T-cell lymphoma-approved Beleodaq^®, in combination with checkpoint inhibitors as a potential treatment option for other tumor indications. [Onxeo S.A.] Press Release

Bellicum and Ospedale Pediatrico Bambino Gesù Announce Expanded Collaboration to Develop Novel CAR T and TCR Cell Therapies Engineered with CaspaCIDe

Bellicum Pharmaceuticals, Inc. and Ospedale Pediatrico Bambino Gesù announced that they have entered into an expanded collaboration focused on preclinical and clinical development of CD19 and other CAR T and TCR therapeutics engineered with Bellicum’s CaspaCIDe^® molecular safety switch technology. [Bellicum Pharmaceuticals, Inc.] Press Release

Publisher Pulls 58 Articles by Iranian Scientists over Authorship Manipulation

A tranche of 58 articles authored by 282 Iran-based researchers were retracted by a leading scientific publisher, which said it had found signs that the peer review and publication processes had been compromised. [Nature News] Editorial

Young Scientists Ditch Postdocs for Biotech Start-Ups

There is a vanguard of young biomedical scientists who have started companies instead of taking the conventional academic path and pursuing postdoctoral studies after their PhDs. Among the factors driving this change are an infusion of money into early-stage biotech investing, the emergence of biotech incubators and the scarcity of academic jobs in science. [Nature News] Editorial

Beyond Trump vs Clinton: A Scientist’s Guide to the US Election

Choices that voters make will influence other levels of government — and some of these decisions will steer the course of science and science policy. [Nature News] Editorial

NEW 2017 European Cancer Congress
January 27-30, 2017
Amsterdam, Netherlands

Visit our events page to see a complete list of events in the community.

NEW Postdoctoral Position – Physical Oncology (Houston Methodist Research Institute)

NEW Assistant, Associate or Full Professor – Cancer Biology (University of Pennsylvania)

Research Scientist – Epigenetic Mechanisms Involving Histone Deacetylases, Methyltransferases and Demethylases (The University of Texas MD Anderson Cancer Center)

Lecturer – Cancer Biology (NUI Galway)

Associate Professor – Experimental Radiation Oncology (The University of Texas MD Anderson Cancer Center)

Assistant Professor (Tenure Track) – Mechanisms Related to Aging, Cancer and Stem Cell Biology)

Scientific Developer – Computational Systems Biology of Cancer (Institut Curie)

Post-Doctoral Researcher – Influential Nodes and Links in Multi-Level Cancer-Related Networks (Luxembourg Institute of Health)

Two Assistant Professor Positions – Molecular Medicine (University of Georgia)

Postdoctoral Associate – Glioma Stem Cell Biology and Cerebral Organoid (Weill Cornell Medicine)

Postdoctoral Positions – Stem Cell Research, Hematopoiesis, Cancer, Genome Editing (Icahn School of Medicine at Mount Sinai)

Postdoctoral Position – Tumor Immunology (Memorial Sloan Kettering Cancer Center)

Associate Scientist – Epigenetics of Cancer (Celgene Corporation)

Postdoctoral Position – Metastatic Breast Cancer (Purdue Center for Cancer Research)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Cancer Stem Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.